سوق السلفوناميدات - النمو والاتجاهات وتأثير COVID-19 والتوقعات (2023 - 2028)

Table of Contents

1. 1. INTRODUCTION

   1. 1.1 Study Deliverables

   2. 1.2 Study Assumptions

   3. 1.3 Scope of the Study

2. 2. RESEARCH METHODOLOGY

3. 3. EXECUTIVE SUMMARY

4. 4. MARKET DYNAMICS

   1. 4.1 Market Overview

   2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Chronic Diseases Worldwide

      2. 4.2.2 Growing R&D Activities in Pharmaceutical Companies

   3. 4.3 Market Restraints

      1. 4.3.1 Increasing Side Effects associated with the Use of Sulfa Drugs

      2. 4.3.2 Availability of Substitute Drugs

   4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

5. 5. MARKET SEGMENTATION

   1. 5.1 By Route of Administration

      1. 5.1.1 Oral

      2. 5.1.2 Topical

   2. 5.2 By Application

      1. 5.2.1 Skin Infections

      2. 5.2.2 Gastro Intestinal Tract (GIT) Infection

      3. 5.2.3 Urinary Tract Infection (UTI)

      4. 5.2.4 Respiratory Tract Infection (RTI)

      5. 5.2.5 Others

   3. 5.3 Geography

      1. 5.3.1 North America

         1. 5.3.1.1 United States

         2. 5.3.1.2 Canada

         3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

         1. 5.3.2.1 Germany

         2. 5.3.2.2 United Kingdom

         3. 5.3.2.3 France

         4. 5.3.2.4 Italy

         5. 5.3.2.5 Spain

         6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

         1. 5.3.3.1 China

         2. 5.3.3.2 Japan

         3. 5.3.3.3 India

         4. 5.3.3.4 Australia

         5. 5.3.3.5 South Korea

         6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

         1. 5.3.4.1 GCC

         2. 5.3.4.2 South Africa

         3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

         1. 5.3.5.1 Brazil

         2. 5.3.5.2 Argentina

         3. 5.3.5.3 Rest of South America

6. 6. COMPETITIVE LANDSCAPE

   1. 6.1 Company Profiles

      1. 6.1.1 AA Pharma Inc.

      2. 6.1.2 Abbott Laboratories

      3. 6.1.3 F. Hoffmann-La Roche Ltd

      4. 6.1.4 GlaxoSmithKline plc

      5. 6.1.5 Lexine Technochem Pvt. Ltd.

      6. 6.1.6 Mylan Pharmaceuticals

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Teva Pharmaceuticals USA, Inc.

   *List Not Exhaustive

7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS